Adalimumab treatment in intestinal Behçet's disease: Relationship with ectopic mucin 5AC glycoprotein expression and endoscopic improvement

Dig Liver Dis. 2015 Nov;47(11):991-2. doi: 10.1016/j.dld.2015.07.007. Epub 2015 Jul 17.

Authors

Tsutomu Mizoshita¹, Satoshi Tanida², Takashi Joh²

Affiliations

¹ Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Electronic address: tmizoshi@med.nagoya-cu.ac.jp.
² Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

PMID: 26250949
DOI: 10.1016/j.dld.2015.07.007

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adalimumab / therapeutic use*
Antirheumatic Agents / therapeutic use*
Behcet Syndrome / drug therapy*
Cecum / metabolism
Endoscopy, Digestive System
Humans
Ileum / metabolism
Immunohistochemistry
Intestinal Diseases / drug therapy*
Intestinal Diseases / metabolism
Mucin 5AC / metabolism
Treatment Outcome
Ulcer / drug therapy*
Ulcer / metabolism

Substances

Antirheumatic Agents
Mucin 5AC
Adalimumab